Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.04.22	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
21.04.22	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
19.04.22	Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
04.04.22	Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings (Businesswire)
27.03.22	AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
15.03.22	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
03.03.22	Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Businesswire)
28.02.22	Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates (Businesswire)
03.02.22	Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference (Businesswire)
04.01.22	Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences (Businesswire)
09.12.21	Pre-market Movers: ENSC, RETA, CCNC, PEAR, SYTA… (RTTNews)
09.12.21	Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) (Businesswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
17.08.21	Aurinia Pharmaceuticals Declines 9% Following Acquisition Of Two Pipeline Assets (RTTNews)
30.06.21	Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs (Businesswire)
25.06.21	Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) (Businesswire)
14.06.21	Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors (Businesswire)
27.05.21	Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
20.05.21	Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis (Businesswire)
14.05.21	Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences (Businesswire)
10.05.21	Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
10.05.21	Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet (Businesswire)
06.05.21	Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights (Businesswire)
28.04.21	Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021 (Businesswire)
15.04.21	Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
08.04.21	Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings (Businesswire)
15.03.21	Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report (Businesswire)
02.03.21	Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences (Businesswire)
24.02.21	Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (Businesswire)
18.02.21	Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference (Businesswire)
17.02.21	Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 (Businesswire)
23.01.21	FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month (RTTNews)
23.01.21	FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis (Businesswire)
22.01.21	Pre-market Movers In Healthcare Sector: ADMP, FLDM, ATOS, AUPH, SENS... (RTTNews)
11.01.21	Will Aurinia Pharma's Lupus Nephritis Drug Pass FDA Muster? (RTTNews)
08.01.21	Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences (Businesswire)
29.12.20	Biotech Stocks Facing FDA Decision In January 2021 (RTTNews)
17.12.20	Aurinia gibt Kooperations- und Lizenzvertrag mit Otsuka Pharmaceutical Co., Ltd. über die Entwicklung und Vermarktung von Voclosporin in Europa und Japan bekannt (Businesswire)
17.12.20	Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan (Businesswire)
15.12.20	Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity (Businesswire)
02.12.20	Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
20.11.20	Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.11.20	Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference (Businesswire)
10.11.20	Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
09.11.20	Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 (Businesswire)
03.11.20	AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial (RTTNews)
02.11.20	Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome (Businesswire)
28.10.20	AUPH Initiates VOCOVID Trial, KALA Gets FDA Nod, NVAX Expands COVID-19 Vaccine Study Size In UK (RTTNews)
27.10.20	Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 (Businesswire)
22.10.20	Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten